In the article by McCrimmon et al.,¹ the following errors require amendments.

Footnotes for Table 1 should be corrected and updated in the Table as well. The data shown in Table 1 were correct and remain unaltered. The updated footnotes are shown below:

^aiGlarLixi dose adjustments were based on once-daily fasting SMPG measurements;

^bThe U/day refers solely to the iGlar component of iGlarLixi;

^cBIAsp 30 titration utilized pre-dinner SMPG values for breakfast dose adjustment and pre-breakfast SMPG values for dinner dose adjustment.

Dose adjustments were made weekly. BIAsp 30, biphasic insulin aspart 30 (30% insulin aspart and 70% insulin aspart protamine); iGlarLixi, once-daily titratable fixed-ratio combination of basal insulin glargine 100 units/mL and the glucagon-like peptide-1 receptor agonist lixisenatide; SMPG, self-monitored plasma glucose.

In Table 3, data regarding prior basal insulin used at baseline have been corrected and the updated values are shown below; all other data in the table were correct. The footnote for the rows ‘Average basal insulin daily dose (U)’ and ‘Average basal insulin daily dose (U/kg), in Table 3 should be corrected to ^f.

In Section 3.1 titled Baseline characteristics, the sentence regarding the basal insulin used at baseline should be corrected (in line with the Table 3 amendments) to read as:

The most common prior basal insulin used at baseline was insulin glargine 100 U/mL (45.8%), followed by insulin glargine 300 U/mL (21.6%), neutral protamine Hagedorn (NPH) insulin (20.7%), insulin detemir (7.3%) and insulin degludec (4.5%).

The online version of the article has been corrected to reflect the above changes including amendments to in-text citation of references where necessary for accuracy. References 8 (Haluzík et al.) and 15 (Rosenstock et al.) have also been removed.

We apologize for the inconvenience caused.

在 McCrimmon 等人的文章中，¹以下错误需要修正。

表 1 的脚注也应在表中更正和更新。表 1 中显示的数据是正确的并且保持不变。更新后的脚注如下所示：

^a iGlarLixi 剂量调整基于每天一次的空腹 SMPG 测量值；

^b U/day 仅指 iGlarLixi 的 iGlar 组件；

^c BIAsp 30 滴定利用餐前 SMPG 值进行早餐剂量调整和早餐前 SMPG 值进行晚餐剂量调整。

每周进行剂量调整。BIAsp 30，双相门冬胰岛素 30（30% 门冬胰岛素和 70% 门冬胰岛素鱼精蛋白）；iGlarLixi，基础甘精胰岛素 100 单位/mL 和胰高血糖素样肽-1 受体激动剂 lixisenatide 的每日一次可滴定固定比例组合；SMPG，自我监测的血浆葡萄糖。

在表 3 中，关于在基线时使用的先前基础胰岛素的数据已经过校正，更新后的值如下所示；表中的所有其他数据都是正确的。表 3 中“平均基础胰岛素日剂量 (U)”和“平均基础胰岛素日剂量 (U/kg)”行的脚注应更正为^f。

在标题为基线特征的第 3.1 节中，关于基线时使用的基础胰岛素的句子应更正（与表 3 修订一致）改为：

基线时最常见的既往基础胰岛素是甘精胰岛素 100 U/mL (45.8%)，其次是甘精胰岛素 300 U/mL (21.6%)、中性鱼精蛋白 Hagedorn (NPH) 胰岛素 (20.7%)、地特胰岛素 (7.3 %) 和德谷胰岛素 (4.5%)。

文章的在线版本已更正以反映上述更改，包括在必要时对参考文献的文本引用进行修正以确保准确性。参考文献 8（Haluzík 等）和 15（Rosenstock 等）也已删除。

对于造成的不便，我们深表歉意。